Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Novel immune therapies in the future of myeloma treatment – a hot topic at COMy 2022

Mohamad Mohty • 28 Feb 2022
COMy 2022
Multiple Myeloma Antibodies CAR-T

There are several immune therapies, including CAR-T cells and bispecific antibodies, that have changed the treatment landscape of multiple myeloma over the last few years and are constantly evolving. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the importance of better understanding these immune therapies and issues including toxicity management, which will all be discussed by experts at the COMy 2022 congress in Paris, France.

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals